Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter 2026 operating and financial results. President and CEO Panna Sharma, along with other management team members, will review the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company's RADR(R) and Open-Medicine AI platforms. A replay will be available on the investor relations section of Lantern Pharma's website after the event.
The announcement comes as Lantern Pharma continues to integrate AI across its oncology pipeline. Its proprietary RADR platform uses machine learning to analyze cancer data and identify patient populations most likely to respond to its therapies. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned subsidiary.
Beyond its pipeline, Lantern has made strides in commercializing its AI capabilities. The company's Zeta.ai platform, a multi-agentic AI co-scientist, is now available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream. This move positions Lantern not only as a drug developer but also as a provider of AI tools to the broader research community. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The webcast is expected to shed light on how Lantern plans to leverage its AI platforms to accelerate drug development and generate revenue. Investors will be keen to hear about the progress of its clinical trials, particularly the HARMONIC trial, and any updates on the commercial adoption of Zeta.ai. The company's ability to monetize its AI technology could provide a diversified income source, reducing reliance on traditional funding mechanisms.
Lantern Pharma's approach reflects a broader trend in the biotech industry toward using AI to improve success rates in oncology drug development. By identifying biomarkers and patient subgroups, AI can potentially reduce trial sizes and shorten timelines. The company's focus on AI-driven precision medicine may set a precedent for how other firms leverage machine learning to streamline drug discovery and development.
As the webcast approaches, investors and industry watchers will monitor for any announcements regarding trial data, regulatory milestones, or partnership opportunities. The integration of AI into oncology is still evolving, and Lantern's progress could offer valuable insights into the practical application of these technologies in clinical settings. The company's next quarterly update will be a critical juncture for evaluating its strategic direction and operational performance.
For more information, visit the full press release and Lantern Pharma's newsroom.
